InhaleRx Limited (IRX.AX)
- Previous Close
0.0270 - Open
0.0250 - Bid 0.0270 x --
- Ask 0.0400 x --
- Day's Range
0.0250 - 0.0270 - 52 Week Range
0.0180 - 0.0500 - Volume
157,753 - Avg. Volume
70,810 - Market Cap (intraday)
5.763M - Beta (5Y Monthly) -0.08
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date Feb 26, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
InhaleRx Limited, a biotechnology company, develops and sells registrable inhaled drug-device combinations in Australia. It is developing IRX-211 that has completed Phase 1 clinical trial for the treatment of Breakthrough Cancer Pain (BTcP); and IRX-616a that is in preclinical trial for panic disorder (PD). The company was formerly known as Lifespot Health Ltd and changed its name to InhaleRx Limited in October 2021. InhaleRx Limited was incorporated in 2016 and is headquartered in Melbourne, Australia.
inhalerx.com.auRecent News: IRX.AX
View MorePerformance Overview: IRX.AX
Trailing total returns as of 5/21/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IRX.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IRX.AX
View MoreValuation Measures
Market Cap
5.76M
Enterprise Value
5.60M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-69.85%
Return on Equity (ttm)
-402.12%
Revenue (ttm)
401.81k
Net Income Avi to Common (ttm)
-1.21M
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
194.91k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-95.17k